3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 2/3
1
Phase 1
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Stomach Neoplasms
5
Gastrointestinal Neoplasms
3
Pancreatic Neoplasms
2
Esophageal Neoplasms
2
Rectal Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Colonic Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
Cisplatin
88
Fluorouracil
71
Paclitaxel
69
Radiotherapy
63
Oxaliplatin
55
Irinotecan
37
Docetaxel
36
Carboplatin
36
Leucovorin
34
Capecitabine
28
Radiation
25
Surgical Procedures, Operative
22
Drug Therapy
19
pembrolizumab
18
Cetuximab
15
Bevacizumab
15
Nivolumab
14
tislelizumab
12
camrelizumab
11
Neoadjuvant Therapy
11
Esophagectomy
11
Chemoradiotherapy
11
S 1 (combination)
10
Albumin-Bound Paclitaxel
10
nimotuzumab
9
Trastuzumab
9
durvalumab
8
Radiotherapy, Intensity-Modulated
8
Gefitinib
7
Epirubicin
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Esophageal Neoplasms
×
tegafur-gimeracil-oteracil
×
Clear all
NCT02128243
2021-03-26
MATEO
AIO-Studien-gGmbH
Phase 2
Completed
242 enrolled
NCT02216149
2018-08-28
FluoHeart
Helsinki University Central Hospital
Phase 2
Terminated
20 enrolled